Author

J. Schuhenn

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cell Biology· 1 Immunology· 1 Microbiology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 3 Organism:human· 3 Assay:bulk RNA-seq· 2 Research Focus:host-pathogen & immune response· 2 Research Focus:drug response / drug discovery· 1 Assay:proteomics· 1

Frequent Co-Authors

K. Sutter· 3 shared U. Dittmer· 3 shared C. Elsner· 2 shared M. Trilling· 2 shared V. T. K. Le-Trilling· 2 shared Z. Karakoese· 2 shared A. Krawczyk· 1 shared B. Bleekmann· 1 shared

Activity by Year

2021-2023 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 39 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

3 shared papersImmunology

K. Sutter

Mutual co-authors in cluster

Author profile →

3 papers

Recent·Most cited

Targeted mutations in IFNα2 improve its antiviral activity against various viruses

Z. Karakoese, V. T. K. Le-Trilling, J. Schuhenn, S. Francois, M. Lu, J. Liu, M. Trilling, D. Hoffmann, U. Dittmer, K. Sutter

The paper identifies critical antiviral residues in IFN subtypes and designs improved IFN molecules with enhanced antiviral activity against HIV and HBV.

bioRxiv · Sep 6, 2023Immunology

Interferon-α subtype treatment induces the repression of SRSF1 in HIV-1 target cells and affects HIV-1 post integration steps

H. Sertznig, F. Roesmann, B. Bleekmann, C. Elsner, M. L. Santiago, J. Schuhenn, Y. Benatzy, R. Snodgrass, S. Esser, K. Sutter, U. Dittmer, M. Widera

This study shows that IFN-α treatment represses SRSF1 in HIV-1 target cells, affecting post-integration viral replication steps by altering splicing and transcription.

bioRxiv · Jun 11, 2021 · PreprintMicrobiology

Differential interferon-α subtype immune signatures suppress SARS-CoV-2 infection

J. Schuhenn, T. L. Meister, D. Todt, T. Bracht, K. Schork, J.-N. Billaud, C. Elsner, N. Heinen, Z. Karakoese, S. Haid, S. Kumar, L. Brunotte, M. Eisenacher, J. Chen, Z. Yuan, , S. Pfaender

The paper identifies differential antiviral effects of IFN-alpha subtypes against SARS-CoV-2 and highlights IFN5's superior activity, suggesting therapeutic potential.

bioRxiv · May 20, 2021 · PreprintCell Biology